Medical Hair Loss Therapy
Dermatologist-led Clinical Therapies to Treat Hair Loss and Scalp Disease.
HMI Medical Hair Loss Protocol™
Hair loss is a chronic, biologically driven process. In genetically susceptible individuals, follicles gradually miniaturize under hormonal and cellular signaling—leading to thinning, shorter growth cycles, and eventual dormancy.
The goal of the HMI Medical Protocol is biologic stabilization: slowing or halting this process while preserving as much native hair as possible.
Because once a follicle is lost, medication cannot reliably restore it, early and consistent treatment is critical.
Core Principals
- Hair loss is chronic, not episodic
- Medical therapy only works while continued
- Combination therapy outperforms monotherapy
- Consistency matters more than intensity
- Preserving native hair improves all long-term outcomes, including surgery
Androgen Modulation
Androgen signaling—particularly the effect of DHT on susceptible follicles—is a primary driver of pattern hair loss.
The HMI Medical Protocol targets this process through complementary mechanisms, selected based on sex, biology, and risk profile.
DHT Reduction
Finasteride / Dutasteride (Oral or Topical)
These medications reduce the conversion of testosterone to DHT by inhibiting 5-alpha reductase enzymes.
Clinical effects:
- Slows or halts miniaturization
- Preserves existing density
- May stimulate regrowth in partially miniaturized follicles
Clinical use:
- Finasteride is typically first-line
- Dutasteride provides more complete suppression and is used selectively
In women, DHT-lowering therapy is used selectively—most often post-menopause or with reliable contraception—based on individual risk.
Androgen Receptor Blockade
Clascoterone (Topical)
Clascoterone blocks DHT at the follicle receptor level without lowering systemic hormone levels.
Why it matters:
- Local control of androgen signaling
- Minimal systemic exposure
- Appropriate for both men and women
- Ideal for patients avoiding systemic DHT suppression
Used alone in mild cases or layered with systemic therapy for added control.
Additional Androgen Modulation
Spironolactone (Oral — when appropriate)
Spironolactone reduces follicular sensitivity to circulating androgens.
Clinical role:
- Commonly used in women with hormonally driven loss
- Does not increase estrogen levels
- Requires appropriate contraception in women of childbearing potential
Growth Stimulation
Minoxidil (Topical or Low-Dose Oral)
Minoxidil remains a cornerstone therapy for both men and women.
Mechanisms:
- Prolongs the anagen (growth) phase
- Increases hair shaft diameter
- Improves blood flow and cellular signaling
Low-dose oral minoxidil is increasingly favored for its simplicity and long-term adherence when appropriate.
Combination Medical Therapy
Hair loss is rarely driven by a single pathway. For this reason, combination therapy consistently delivers superior long-term results.
At HMI, we follow a simple principle:
The best plan is the one you can stay on.
When appropriate, custom compounding is used to:
- Reduce pill burden
- Minimize topical complexity
- Simplify daily routines
- Match treatment intensity to individual biology and tolerance
Many patients are maintained on a single, once-daily oral formulation, with topical therapy added selectively.
Monitoring & Adjustment
- Confirm stabilization
- Track density and caliber changes
- Adjust therapy based on response and tolerance
Medical therapy is dynamic. Ongoing evaluation ensures treatment remains aligned with long-term goals.
Relevance to Surgery
Medical therapy is essential both before and after hair transplantation.
It:
- Preserves surrounding native hair
- Reduces post-operative shock loss
- Improves long-term density
- Enhances graft survival
At HMI, medical therapy is strongly encouraged for surgical candidates unless contraindicated—and remains necessary to maintain results.
The HMI Approach
At Hair Medicine Institute, medical therapy is not generic—it is personalized, structured, and designed for real-world adherence.
The objective is not short-term regrowth, but long-term control, preservation, and flexibility within a comprehensive biologic strategy.